Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Effects of control interventions on Clostridium difficile infection in England: an observational study.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, Harding RM, Wilson DJ, Griffiths D, Vaughan A, Finney JM, Wyllie DH, Oakley SJ, Fawley WN, Freeman J, Morris K, Martin J, Howard P, Gorbach S, Goldstein EJC, Citron DM, Hopkins S, Hope R, Johnson AP, Wilcox MH, Peto TEA, Walker AS, Crook DW; Modernising Medical Microbiology Informatics Group.

Lancet Infect Dis. 2017 Apr;17(4):411-421. doi: 10.1016/S1473-3099(16)30514-X. Epub 2017 Jan 25.

2.

Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis.

Lawes T, Lopez-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Wares KD, Sinclair C, Gould IM.

Lancet Infect Dis. 2017 Feb;17(2):194-206. doi: 10.1016/S1473-3099(16)30397-8. Epub 2016 Nov 4.

PMID:
27825595
3.

Diverse sources of C. difficile infection identified on whole-genome sequencing.

Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, Ip CLC, Golubchik T, Batty EM, Finney JM, Wyllie DH, Didelot X, Piazza P, Bowden R, Dingle KE, Harding RM, Crook DW, Wilcox MH, Peto TEA, Walker AS.

N Engl J Med. 2013 Sep 26;369(13):1195-205. doi: 10.1056/NEJMoa1216064.

4.

Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.

Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E.

Lancet Infect Dis. 2017 Sep;17(9):990-1001. doi: 10.1016/S1473-3099(17)30325-0. Epub 2017 Jun 16. Review.

PMID:
28629876
5.

Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures.

Aldeyab MA, Devine MJ, Flanagan P, Mannion M, Craig A, Scott MG, Harbarth S, Vernaz N, Davies E, Brazier JS, Smyth B, McElnay JC, Gilmore BF, Conlon G, Magee FA, Elhajji FW, Small S, Edwards C, Funston C, Kearney MP.

Infect Control Hosp Epidemiol. 2011 Mar;32(3):210-9. doi: 10.1086/658333.

PMID:
21460505
6.

Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.

Nyc O, Tejkalova R, Kriz Z, Ruzicka F, Kubicek L, Matejkova J, Kuijper E, Krutova M.

Microb Drug Resist. 2017 Jul;23(5):609-615. doi: 10.1089/mdr.2016.0159. Epub 2016 Nov 18.

PMID:
27860531
8.

Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England.

Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, Birtles A, Cairns M, Curran MD, Dodgson KJ, Green SM, Hardy KJ, Hawkey PM, Magee JG, Sails AD, Wren MW.

Clin Infect Dis. 2012 Oct;55(8):1056-63. Epub 2012 Jul 11.

PMID:
22784871
9.

Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.

Kanerva M, Ollgren J, Voipio T, Mentula S, Lyytikäinen O.

Infect Dis (Lond). 2015 Aug;47(8):530-5. doi: 10.3109/23744235.2015.1026933. Epub 2015 Apr 2.

PMID:
25832317
10.

Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis.

Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T, Woolfrey S.

J Hosp Infect. 2015 Sep;91(1):74-80. doi: 10.1016/j.jhin.2015.05.013. Epub 2015 Jun 21.

PMID:
26169793
11.

Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection.

Shea KM, Hobbs ALV, Jaso TC, Bissett JD, Cruz CM, Douglass ET, Garey KW.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00125-17. doi: 10.1128/AAC.00125-17. Print 2017 Jun.

12.

Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.

Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmée M, Kuijper E, Poxton IR; European Study Group on Clostridium difficile (ESGCD).

J Med Microbiol. 2008 Jun;57(Pt 6):784-9. doi: 10.1099/jmm.0.47738-0.

PMID:
18480338
13.

Comparison of Control of Clostridium difficile Infection in Six English Hospitals Using Whole-Genome Sequencing.

Eyre DW, Fawley WN, Rajgopal A, Settle C, Mortimer K, Goldenberg SD, Dawson S, Crook DW, Peto TEA, Walker AS, Wilcox MH.

Clin Infect Dis. 2017 Aug 1;65(3):433-441. doi: 10.1093/cid/cix338.

14.

Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.

López-Ureña D, Quesada-Gómez C, Montoya-Ramírez M, del Mar Gamboa-Coronado M, Somogyi T, Rodríguez C, Rodríguez-Cavallini E.

Emerg Microbes Infect. 2016 May 11;5:e42. doi: 10.1038/emi.2016.38.

15.

Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence.

Kumar N, Miyajima F, He M, Roberts P, Swale A, Ellison L, Pickard D, Smith G, Molyneux R, Dougan G, Parkhill J, Wren BW, Parry CM, Pirmohamed M, Lawley TD.

Clin Infect Dis. 2016 Mar 15;62(6):746-752. doi: 10.1093/cid/civ1031. Epub 2015 Dec 18.

16.

Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.

Walbrown MA, Aspinall SL, Bayliss NK, Stone RA, Cunningham F, Squier CL, Good CB.

J Manag Care Pharm. 2008 Jan-Feb;14(1):34-40.

17.

Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007.

Karlowsky JA, Zhanel GG, Hammond GW, Rubinstein E, Wylie J, Du T, Mulvey MR, Alfa MJ.

J Med Microbiol. 2012 May;61(Pt 5):693-700. doi: 10.1099/jmm.0.041053-0. Epub 2012 Feb 2.

PMID:
22301615
18.

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost.

Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM.

Ann Intern Med. 1998 Jun 15;128(12 Pt 1):989-95.

PMID:
9625685
19.

Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission.

Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH.

Clin Infect Dis. 2013 Oct;57(8):1094-102. doi: 10.1093/cid/cit475. Epub 2013 Jul 23.

20.

Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system.

McFarland LV, Clarridge JE, Beneda HW, Raugi GJ.

Clin Infect Dis. 2007 Nov 1;45(9):1141-51. Epub 2007 Sep 26.

PMID:
17918075

Supplemental Content

Support Center